Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 2
2007 6
2008 6
2009 4
2010 3
2011 5
2012 3
2013 5
2014 8
2015 9
2016 9
2017 6
2018 12
2019 10
2020 8
2021 4
2022 11
2023 10
2024 6
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Review of rifaximin as treatment for SIBO and IBS.
Pimentel M. Pimentel M. Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175. Expert Opin Investig Drugs. 2009. PMID: 19243285 Review.
Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). OBJECTIVE: To review rifaximin for treatment …
Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including …
Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study).
Guo H, Lu S, Zhang J, Chen C, Du Y, Wang K, Duan L. Guo H, et al. Front Pharmacol. 2023 Feb 15;14:1121435. doi: 10.3389/fphar.2023.1121435. eCollection 2023. Front Pharmacol. 2023. PMID: 36873985 Free PMC article.
Potential effect of berberine to the gut may provide therapeutic target for SIBO. We aimed to evaluate the effect of berberine compared with rifaximin on SIBO patients. ...The primary hypothesis is that berberine is not inferior to rifaximin for SIB …
Potential effect of berberine to the gut may provide therapeutic target for SIBO. We aimed to evaluate the effect of berberine compar …
Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.
Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Chedid V, et al. Glob Adv Health Med. 2014 May;3(3):16-24. doi: 10.7453/gahmj.2014.019. Glob Adv Health Med. 2014. PMID: 24891990 Free PMC article.
The objective was to determine the remission rate of SIBO using either the antibiotic rifaximin or herbals in a tertiary care referral gastroenterology practice. ...Herbals also appear to be as effective as triple antibiotic therapy for SIBO rescue therapy fo …
The objective was to determine the remission rate of SIBO using either the antibiotic rifaximin or herbals in a tertiary care …
Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.
Rao SSC, Bhagatwala J. Rao SSC, et al. Clin Transl Gastroenterol. 2019 Oct;10(10):e00078. doi: 10.14309/ctg.0000000000000078. Clin Transl Gastroenterol. 2019. PMID: 31584459 Free PMC article. Review.
Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. ...Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be …
Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO …
The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO).
Quigley EMM. Quigley EMM. Curr Gastroenterol Rep. 2019 Jan 15;21(1):3. doi: 10.1007/s11894-019-0671-z. Curr Gastroenterol Rep. 2019. PMID: 30645678 Review.
PURPOSE OF REVIEW: To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO). RECENT FINDINGS: While various series continue to illustrate the occurrence of SIBO in disease stat …
PURPOSE OF REVIEW: To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal ba …
Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis.
Wang J, Zhang L, Hou X. Wang J, et al. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1385-1399. doi: 10.1080/17474124.2021.2005579. Epub 2021 Nov 26. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34767484
OBJECTIVES: Over the past decades, rifaximin has been used to treat with small intestinal bacterial overgrowth (SIBO), however, the true efficacy remains unknown. ...Subgroup analysis and meta-regression indicated a dose-dependent eradication rate of rifaximin …
OBJECTIVES: Over the past decades, rifaximin has been used to treat with small intestinal bacterial overgrowth (SIBO), however …
Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.
Gatta L, Scarpignato C. Gatta L, et al. Aliment Pharmacol Ther. 2017 Mar;45(5):604-616. doi: 10.1111/apt.13928. Epub 2017 Jan 12. Aliment Pharmacol Ther. 2017. PMID: 28078798 Free PMC article.
AIM: To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate SIBO in adult patients. METHODS: MEDLINE, EMBASE, CCRCT, Scopus and Web of Science were searched from inception to March 16, 2015 for …
AIM: To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate …
How to Recognize and Treat Small Intestinal Bacterial Overgrowth?
Skrzydło-Radomańska B, Cukrowska B. Skrzydło-Radomańska B, et al. J Clin Med. 2022 Oct 12;11(20):6017. doi: 10.3390/jcm11206017. J Clin Med. 2022. PMID: 36294338 Free PMC article. Review.
The prevalence of SIBO over recent decades has been estimated to range from 2.5 to 22% (depending on the source) and to increase with age and among individuals with comorbidities. ...However, SIBO is still both a diagnostic and a therapeutic problem. This review pre …
The prevalence of SIBO over recent decades has been estimated to range from 2.5 to 22% (depending on the source) and to increase with …
Show Me What You Have Inside-The Complex Interplay between SIBO and Multiple Medical Conditions-A Systematic Review.
Sroka N, Rydzewska-Rosołowska A, Kakareko K, Rosołowski M, Głowińska I, Hryszko T. Sroka N, et al. Nutrients. 2022 Dec 24;15(1):90. doi: 10.3390/nu15010090. Nutrients. 2022. PMID: 36615748 Free PMC article.
In recent years there has been growing interest in the influence of SIBO and its impact on the whole human body as well as individual systems. Therefore, we aimed to investigate the co-existence of SIBO with different medical conditions. ...Although more research is …
In recent years there has been growing interest in the influence of SIBO and its impact on the whole human body as well as individual …
How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach.
Rezaie A, Pimentel M, Rao SS. Rezaie A, et al. Curr Gastroenterol Rep. 2016 Feb;18(2):8. doi: 10.1007/s11894-015-0482-9. Curr Gastroenterol Rep. 2016. PMID: 26780631 Review.
However, there is a lack of standardization of these tests and their interpretation. Treatment of SIBO remains empirical; generally, broad spectrum antibiotics are recommended for 2 weeks (amoxicillin, rifaximin, ciprofloxacin, etc.) but evidence for their use is fa …
However, there is a lack of standardization of these tests and their interpretation. Treatment of SIBO remains empirical; generally, …
132 results